Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (31-40 of 252) with videos related to

Pageof 26
Sort By:
Alimentary Pharmacology & Therapeutics|August 23, 2021
Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?Pauline Veyrard, Stéphane Nancey, Xavier Roblin
Expert Opinion on Investigational Drugs|February 17, 2018
Filgotinib for the treatment of Crohn's diseaseRemi Labetoulle, Stephane Paul, Xavier Roblin
Gastroenterology|November 10, 2019
The Simplified Magnetic Resonance Index of Activity (MARIA) for Crohn's Disease Is Strongly Correlated With the MARIA and Clermont Score: An External ValidationNicolas Williet, Sabine Jardin, Xavier Roblin
Alimentary Pharmacology & Therapeutics|February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie gameXavier Roblin, Stéphane Paul, Stéphane Nancey
Journal of Crohn'S & Colitis|November 1, 2017
Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated SpondyloarthropathyXavier Roblin, Stéphane Paul, Shomron Ben-Horin
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2023
Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to ConcludeEdward V Loftus, Stephàne Paul, Xavier Roblin
Gastroenterology|November 26, 2013
Does anti-TNF therapy cost so many COINs?Xavier Roblin, Silvio Danese, Laurent Peyrin-Biroulet
Alimentary Pharmacology & Therapeutics|February 28, 2019
Letter: double-dose intensification-a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors replyBella Ungar, Shomron Ben Horin, Xavier Roblin
Journal of Crohn'S & Colitis|April 29, 2020
Prospective Evaluation of Cytomegalovirus Time-course Kinetics in Colonic Biopsies from Patients with Moderate-to-severe Ulcerative Colitis Following Infliximab Treatment: A Prospective StudyLucile Boivineau, Anthony Le Méhauté, Xavier Roblin
Alimentary Pharmacology & Therapeutics|October 29, 2020
Editorial: therapeutic drug monitoring for golimumab - ready for prime time?Xavier Roblin, Bertrand Le Roy, Stéphane Paul
Pageof 26

Showing results (31-40 of 252) with videos related to

Sort By:
Pageof 26
Alimentary Pharmacology & Therapeutics|August 23, 2021
Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?Pauline Veyrard, Stéphane Nancey, Xavier Roblin
Expert Opinion on Investigational Drugs|February 17, 2018
Filgotinib for the treatment of Crohn's diseaseRemi Labetoulle, Stephane Paul, Xavier Roblin
Gastroenterology|November 10, 2019
The Simplified Magnetic Resonance Index of Activity (MARIA) for Crohn's Disease Is Strongly Correlated With the MARIA and Clermont Score: An External ValidationNicolas Williet, Sabine Jardin, Xavier Roblin
Alimentary Pharmacology & Therapeutics|February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie gameXavier Roblin, Stéphane Paul, Stéphane Nancey
Journal of Crohn'S & Colitis|November 1, 2017
Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated SpondyloarthropathyXavier Roblin, Stéphane Paul, Shomron Ben-Horin
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 7, 2023
Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to ConcludeEdward V Loftus, Stephàne Paul, Xavier Roblin
Gastroenterology|November 26, 2013
Does anti-TNF therapy cost so many COINs?Xavier Roblin, Silvio Danese, Laurent Peyrin-Biroulet
Alimentary Pharmacology & Therapeutics|February 28, 2019
Letter: double-dose intensification-a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors replyBella Ungar, Shomron Ben Horin, Xavier Roblin
Journal of Crohn'S & Colitis|April 29, 2020
Prospective Evaluation of Cytomegalovirus Time-course Kinetics in Colonic Biopsies from Patients with Moderate-to-severe Ulcerative Colitis Following Infliximab Treatment: A Prospective StudyLucile Boivineau, Anthony Le Méhauté, Xavier Roblin
Alimentary Pharmacology & Therapeutics|October 29, 2020
Editorial: therapeutic drug monitoring for golimumab - ready for prime time?Xavier Roblin, Bertrand Le Roy, Stéphane Paul
Pageof 26